Table 3.

Cardiac magnetic resonance findings at baseline and at 12 months’ follow-up

	AHA segments involved 4 and 5 only		P	AHA segments involved 4, 5 ,6 ,7 ,8 ,9 ,10 ,11 ,12*		P	Total		P
	Baseline	Follow-up		Baseline	Follow-up		Baseline	Follow-up
Number of patients (n)	39	37	NS	12	12	NS	51	49	NS
LVEF (%)	54±8	62±6	0.0022	45±9	55±6	0.0026	45±9	62±6	0.0026
LVEDV (ml)	148±16	128±22	0.0072	158±22	132±25	0.0072	158±25	132±25	0.0072
LVESV (ml)	39±4	34±7	0.0045	42±6	34±5	0.0045	42±6	34±7	0.0045
Segmental hypokinesia, n (%)	39 (57)	-	<0.0001	-	-	-	39 (57)	-	<0.0001
Global hypokinesia, n (%)	-	-	-	12 (18)	12 (18)	0.001	12 (18)	12 (18)	NS
Visible myocardial oedema, n (%)	39 (57)	-	<0.0001	12 (18)	-	<0.0001	51 (75)	-	<0.0001
T2 ratio	2.4±0.2	0.7±0.4	<0.0001	2.6±0.6	0.8±0.2	<0.0001	2.6±0.4	0.8±0.2	<0.0001
EGE, n (%)	32 (47)	-	<0.0001	6 (9)	-	<0.0001	38 (56)	-	<0.0001
EGEr (range)	3.9±1.2	1.6±1.1	<0.0001	4.2±2.2	1.8±1.2	<0.0001	4.2±2.2	1.6±1.4	<0.0001
LGE, n (%)	42 (62)	40 (60)	NS	9 (13)	9 (13)	NS	51 (75)	49 (72)	NS
LGE total extent (%)	16±11	15±9	NS	18±9	17±10	NS	18±12	17±11	NS
Pericardial effusion, n (%)	2 (3%)	-	<0.0001	7 (10)	1 (1)	<0.0001	9 (13)	1 (1)	<0.0001

*P < 0.05 considered statistically significant. AHA: American Heart Association, LV: Left ventricular, LVEF: LV ejection fraction, LVEDV: LV end-diastolic volume, LVESV: LV end-systolic volume, EGE: Early gadolinium enhancement, EGEr: EGE ratio, LGE: Late gadolinium enhancement, NS: Not significance